Oral Anticoagulants Market Snapshot: Big Bucks, But Payers Are On Guard

Pradaxa, the Boehringer Ingelheim drug that FDA approved on Oct. 19, is the first of several oral anti-coagulants that could come on the U.S. market near-term and shake up existing standards of care.